Special Combination of OBP-301 and Pembrolizumab

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

April 6, 2021

Study Completion Date

April 6, 2022

Conditions
Advanced Solid Tumor
Interventions
BIOLOGICAL

OBP-301

"Intratumoral injection directly into the dose target region of a tumor at Day 1, Day 15, and Day 29.~Additional administration of OBP-301 After the recommended dose of OBP-301 has been established, additional administration of OBP-301 is allowed. After completion of administration of OBP-301 on Day 1 - Day 29(+/- 4 days), if the target region has not disappeared, additional administration of OBP-301 is allowed after Day 43 or later.~The patients in Phase 1a, Pembrolizumab administration has continued, are included.~The recommended dose determined in the Phase 1a part will be administered 3 times biweekly (+/- 4 days); max 4 cycles."

DRUG

Pembrolizumab

200 mg Pembrolizumab is infused intravenously at Day 8. Thereafter infusion will continue every 3 weeks until discontinuation.

Trial Locations (1)

Unknown

National Cancer Center Hospital East, Kashiwa

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Oncolys BioPharma Inc

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Toshihiko Doi

OTHER

NCT03172819 - Special Combination of OBP-301 and Pembrolizumab | Biotech Hunter | Biotech Hunter